Organicell Starts Enrolling Long COVID
Trial
Clinical
Trial Update
DAVIE, FL
-- November 17, 2022 --
InvestorsHub NewsWire -- Organicell Regenerative
Medicine, Inc. (OTCQB: OCEL), a clinical-stage biopharmaceutical
company focused on the development of innovative biological
therapeutics and regenerative medicine, is pleased to announce that
the long COVID Clinical Trial is officially active with
enrollment.
"This announcement is an
obligatory update because there has been a change in the status of
our clinical trials, they are now active and enrolled with
patients… but I want this news to be a call to action!" said
Organicell's acting CEO Matt Sinnreich.
He continued "Our team has
been working with the FDA and its Institutional Review Board for
the last six months on the enrollment criteria to make these long
COVID trials enrollable. We have activated new clinical trial sites
in Miami and Los Angeles to reach a larger population of potential
patients to help the trials fully enroll quickly. Our clinical
trial sites are now active, screening, and enrolling patients!"
Organicell has treated 18
people for COVID with Zofin under the
guidance of the FDA's Emergency Investigational New Drug (eIND)
program. The Company has also treated 10 patients under an FDA
approved IND expanded access trial on Moderate COVID, and 8
patients under an FDA approved IND for Moderate to Severe
COVID.
Sinnreich added "Organicell
has published the results of the patients treated with Zofin and the data is compelling. Our
scientists observed the reduction of inflammation in key biomarkers
(IL-6 and CRP) and the structural difference in the lungs after 30
days. The purpose of these long COVID clinical trials is to prove
that Zofin is the reason for these
improvements."
Zofin is a naturally derived,
acellular, exosome-based therapeutic which we believe has naturally
occurring anti-inflammatory properties. Organicell's science team
has been working with the CDC and accredited Universities to
further demonstrate the science to get Zofin into the hands of the
masses.
Bloomberg, Reuters, even
Nature.com have all shined a spotlight on the hundred million plus
people affected by long COVID. There are currently no solutions to
long COVID.
Bloomberg stated in a
November 1st article on
long COVID that "at least 140 million people worldwide are
suffering with long COVID and Harvard University economist David
Cutler puts the total cost of long
Covid in the US at $3.7 trillion. That's equal to more
than 80% of government outlays
for the pandemic through the end of July. And scientists still
don't know what causes it, how many people it affects, or how to
prevent and treat it."
Sinnreich concluded,
"Organicell has the trials set up, but the Company needs the
support of the government in the same way they helped expedite the
COVID vaccine development. Organicell does not have the resources
to spend millions on lobbying, but that does not mean that the
Company should be excluded from government programs.
Now that the midterm
elections are over, it is time we demand our politicians do
something to help us! This virus is not going away. Our goal is to
get the attention of the right people in government to help a
smaller company prove the efficacy of its American-made
therapeutic. With FDA approval, Zofin could have the
potential to help so many people worldwide."
About Organicell Regenerative Medicines,
Inc.
Organicell Regenerative Medicine, Inc. (OTCQB: OCEL) is a clinical-stage biopharmaceutical
company principally focusing on the development of innovative
biological therapeutics for the treatment of degenerative diseases
and the provision of other related services. The Company's
proprietary products are derived from perinatal sources and
manufactured to retain the naturally occurring exosomes, hyaluronic
acid, and proteins without the addition or combination of any other
substance or diluent. To learn more, please visit https://organicell.com/.
Forward-Looking Statements
Certain statements contained in this press release should be
considered forward-looking statements within the meaning of the
Securities Act of 1933, as amended (the "Securities Act"), the
Securities Exchange Act of 1934, as amended (the "Exchange Act"),
and the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are often identified by the use of
forward-looking terminology such as "will", "believes", "expects",
"potential", or similar expressions, involving known and unknown
risks and uncertainties. Although the Company believes that the
expectations reflected in these forward-looking statements are
reasonable, they do involve assumptions, risks and uncertainties,
and these expectations may prove to be incorrect. We remind you
that actual results could vary dramatically as a result of known
and unknown risks and uncertainties, including but not limited to:
potential issues related to our financial condition, competition,
the ability to retain key personnel, product safety, efficacy and
acceptance, the commercial success of any new products or
technologies, success of clinical programs, ability to retain key
customers, our inability to expand sales and distribution channels,
legislation or regulations affecting our operations including
product pricing, reimbursement or access, the ability to protect
our patents and other intellectual property both domestically and
internationally, and other known and unknown risks and
uncertainties, including the risk factors discussed in the
Company's periodic reports that are filed with the SEC and
available on the SEC's website (http://www.sec.gov). You are cautioned not
to place undue reliance on these forward-looking statements. All
forward-looking statements attributable to the Company or persons
acting on its behalf are expressly qualified in their entirety by
these risk factors. Specific information included in this press
release may change over time and may or may not be accurate after
the date of the release. Organicell has no intention and
specifically disclaims any duty to update the information in this
press release.
Investor Relations and Media Relations
Contact
Organicell Investor Relations
1-888-963-7881 Ext.701
IR@organicell.com